Výsledky vyhledávání

Akademický článek

Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib

Autor: Valentina Perrone, Serena Losi, Veronica Rogai, Silvia Antonelli, Walid Fakhouri, Massimo Giovannitti, Elisa Giacomini, Diego Sangiorgi, Luca Degli Esposti

Publikováno v: Rheumatology and Therapy, Vol 7, Iss 3, Pp 657-665 (2020)

Abstract Introduction The objective of this study was to evaluate treatment patterns in patients with rheumatoid arthritis (RA), with a focus on the utilization of baricitinib, an oral highly selective Janus kinase 1 and 2 inhibitor, in an Italian re

Externí odkaz: https://doaj.org/article/7529f53c6e4a491c9f89a82a4723c909

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

The role of patient preferences in adherence to treatment in chronic disease: a narrative review

Autor: Serena Losi, Cesare Celeste Federico Berra, Riccardo Fornengo, Dario Pitocco, Giovanni Biricolti, Marco Orsini Federici

Publikováno v: Drug Target Insights, Vol 15, Iss 1 (2021)

Adherence to prescribed medication is important to the management of all diseases, especially those of chronic nature. Drug effectiveness is substantially compromised by therapy nonadherence. We reviewed the available evidences on the impact of patie

Externí odkaz: https://doaj.org/article/393ee730b4ac48cb847c7a86e303c607

Zobrazit plný text záznamu

Akademický článek

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

Autor: Roberto Ravasio, Antonio Costanzo, Silvia Antonelli, Alessia Maiorino, Serena Losi

Publikováno v: Global & Regional Health Technology Assessment, Vol 8 (2021)

Background: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-t

Externí odkaz: https://doaj.org/article/0ee066a17d7f40bc8cb07526059eb545

Zobrazit plný text záznamu

Akademický článek

[Untitled]

Autor: Roberto Ravasio, Silvia Antonelli, Alessia Maiorino, Antonio Costanzo, Serena Losi

Publikováno v: Global & Regional Health Technology Assessment, Vol 6, Iss 1 (2019)

Externí odkaz: https://doaj.org/article/b15c8206b02b4d86989c8991ead1b867

Zobrazit plný text záznamu

Akademický článek

Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy

Autor: Roberto Ravasio, Silvia Antonelli, Alessia Maiorino, Antonio Costanzo, Serena Losi

Publikováno v: Global & Regional Health Technology Assessment, Vol 2019 (2019)

This analysis was aimed at estimating the cost per responder as measured by number needed to treat of ixekizumab as compared with other biologic drugs approved in Italy for the treatment of moderate-to-severe plaque psoriasis. The clinical efficacy w

Externí odkaz: https://doaj.org/article/3865e7c1e5b34a9d8e11e4532f60129d

Zobrazit plný text záznamu

Akademický článek

Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy

Autor: Roberto Ravasio, Silvia Antonelli, Veronica Rogai, Walid Fakhouri, Jean Philippe Capron, Serena Losi

Publikováno v: Global & Regional Health Technology Assessment, Vol 2018 (2018)

Biological disease-modifying antirheumatic drugs are recommended for use particularly in rheumatoid arthritis patients who had an inadequate response to methotrexate but they are costly. In this article, we estimated the number needed to treat and tr

Externí odkaz: https://doaj.org/article/1513364784ab42c090a89d48e6eae7d7

Zobrazit plný text záznamu